Showing 5421-5430 of 5771 results for "".
- Bausch + Lomb to Launch First-in-Class Surgical Support Applications for Stellaris Elite on IBM Cloudhttps://modernod.com/news/bausch-lomb-to-launch-first-in-class-surgical-support-applications-for-stellaris-elite-on-ibm-cloud/2479752/Bausch + Lomb and IBM announced the launch of the new eyeTELLIGENCE applications which will run on the IBM Cloud to help eye surgeons and surgical facilities work more efficiently using Stellaris Elite vision enhancement systems. The companies built the eyeTELLIGENCE applications to deliver surge
- Optos and Amydis Establish Clinical Alliance to Develop Early Diagnostic Test for Alzheimer’s Diseasehttps://modernod.com/news/optos-and-amydis-establish-clinical-alliance-to-develop-early-diagnostic-test-for-alzheimers-disease/2479754/Optos, a subsidiary of Nikon Corporation, and Amydis announced a clinical alliance focused on the development of an eye test by Amydis to detect Alzheimer’s disease. Amydis has developed a pipeline of compounds to detect amyloid proteins in the retina to be visualized with Optos’ optomap ultra-wi
- Johnson & Johnson Vision to Showcase New Products, Data, Educational Opportunities, and Charitable Giving at 2018 AAOhttps://modernod.com/news/johnson-johnson-vision-to-showcase-new-products-data-educational-opportunities-and-charitable-giving-at-2018-aao/2479756/Johnson & Johnson Vision will showcase the company’s leadership in eye health, innovation and giving at the 2018 American Academy of Ophthalmology’s Annual Meeting (AAO) in Chicago, October 26-30. Johnson & Johnson Vision invented many of the treatments changing the trajectory of e
- Carl Zeiss Meditec to Acquire IanTECH, Maker of the miLOOP Device for Cataract Surgeryhttps://modernod.com/news/carl-zeiss-meditec-to-acquire-iantech-maker-of-the-miloop-device-for-cataract-surgery/2479758/Carl Zeiss Meditec announced it has entered into an agreement to acquire IanTECH, the manufacturer of the miLOOP device for cataract surgery. miLOOP is a microinterventional device designed to deliver energy-free endocapsular lens fragmentation independent of phaco energy. Terms of the d
- Johnson & Johnson Vision Launches MyAcuvue Subscription Programhttps://modernod.com/news/johnson-johnson-vision-launches-myacuvue-subscription-program/2479759/Johnson & Johnson Vision announced the launch of its MyAcuvue Subscription Program, developed to provide contact lens wearers greater access and convenience when purchasing an annual supply of Acuvue Brand contact lenses through their eye care professional. “We continue to look for way
- Ellex to Host an AMD Roundtable During AAO 2018https://modernod.com/news/ellex-to-host-an-amd-roundtable-during-aao-2018/2479760/Ellex Medical Lasers Limited announced that it will partner with a panel of leading ophthalmologists to host a roundtable on age-related macular degeneration (AMD) on Friday, October 26, during the American Academy of Ophthalmology (AAO) meeting in Chicago. “Our goal is to start a serious
- Alcon to Develop SMART Suite Digital Health Platform for Cataract Surgeryhttps://modernod.com/news/alcon-to-develop-smart-suite-digital-health-platform-for-cataract-surgery/2479762/Alcon announced plans to develop the SMART Suite by Alcon, a digital platform that is designed to streamline, simplify, and improve cataract surgery for surgeons and patients. The SMART Suite by Alcon will connect multiple diagnostic and surgical devices through a digital, open cloud-based
- Aerie Pharmaceuticals Establishes GMP PRINT Production Facility in an Expanded Global Headquartershttps://modernod.com/news/aerie-pharmaceuticals-establishes-gmp-print-production-facility-in-an-expanded-global-headquarters/2479763/Aerie Pharmaceuticals announced that it has built and commenced operation of its GMP (Good Manufacturing Practices)-validated manufacturing facility for production of ophthalmic implants using the proprietary PRINT (Particle Replication in Non-wetting Templates) Technology platform. As a result o
- Melt Pharmaceuticals Initiates Clinical Development Program for its Patented MK Melt Conscious Sedation Drug Candidatehttps://modernod.com/news/melt-pharmaceuticals-initiates-clinical-development-program-for-its-patented-mk-melt-conscious-sedation-drug-candidate/2479764/Melt Pharmaceuticals, a subsidiary of Imprimis Pharmaceuticals, announced that following the presentation of clinical data on the MKO Melt (midazolam/ketamine/ondansetron) from a 611-patient IRB approved prospective, controlled, randomized, three arm comparator study at the American Academy of Op
- Cell Care Therapeutics Raises $4.3 Million in Seed Fundinghttps://modernod.com/news/cell-care-therapeutics-raises-4-3-million-in-seed-funding/2479765/Cell Care Therapeutics announced the closing of a $4.3 million seed round investment from a syndicate of individual investors. This round of funding will be used to develop Cell Care’s manufacturing platform and to ad